Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing special use survey of ENHERTU-associated interstitial lung disease in HER2-positive advanced or recurrent gastric cancer
jRCT2001200001Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Sep 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of trastuzumab deruxtecan in gastric cancer (GC), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Drug-related interstitial lung disease. Started Sep 2020; status: completed.
02
Drugs
trastuzumab deruxtecan
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on jRCT2001200001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2001200001.